SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Background of scattered on a plain blue background of many tablets in the form of a silhouette of the continents of the world 3d illustration
Manufacturing
J&J Joins Pharma Peers With $55B US Manufacturing Boost Following Trump’s Tariff Threats
Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major tariffs on pharmaceutical products. Pfizer has also promised a similar commitment.
March 21, 2025
 · 
2 min read
 · 
Annalee Armstrong
Vector illustration representing kidney care, highlighting the importance of health and medical attention for these vital organs
Rare diseases
Novartis’ Fabhalta Approved as First Therapy for Rare Kidney Disease
This is the third indication for Fabhalta after Novartis won FDA approval of the small molecule in paroxysmal nocturnal hemoglobinuria and primary immunoglobulin A nephropathy.
March 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Pictured: Sign at J&J Vision offices in Silicon Valley
FDA
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar challenge.
March 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: CDC signage at its headquarters in Georg
Vaccines
CDC Vaccine Advisors to Meet in April as Trump Eyes New Agency Director
After withdrawing its nomination for Dave Weldon last week, the Trump administration is now reportedly considering Texas Republican Michael Burgess to head the Centers for Disease Control and Prevention.
March 21, 2025
 · 
2 min read
 · 
Tristan Manalac
Man making decision what path, direction to take. Arrows pointing in different directions
Business
Adaptimmune Raises ‘Substantial Doubt’ About Business Despite First-in-Class T Cell Therapy
Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its approval in August 2024. Nevertheless, it is pausing development of two oncology assets to save money.
March 21, 2025
 · 
2 min read
 · 
Tristan Manalac
3D Illustration of Human Heart Anatomy
Cardiovascular disease
Alnylam’s Amvuttra Approved as First RNAi Silencer for Rare Type of Cardiomyopathy
The FDA approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin stabilizers for transthyretin amyloid cardiomyopathy.
March 20, 2025
 · 
8 min read
 · 
Heather McKenzie
medical bottles isolated on blue background, drugs and
Mergers & acquisitions
Paratek Broadens Portfolio With OptiNose Buy Worth up to $330M
Paratek Pharmaceuticals is betting that OptiNose’s chronic rhinosinusitis treatment will be a partner to its antibiotic treatment Nuzyra.
March 20, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
candle flame and sparks home of the fireworks. In the center of the image of the heart"n
Editorial
In Wake of Elevidys Death, Duchenne Patient Community Vows to Push On
After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent Project Muscular Dystrophy stepped up—as they always do.
March 20, 2025
 · 
3 min read
 · 
Annalee Armstrong
Pictured: Blue Sanofi sign on building in Germany at night
I&I
Sanofi Commits up to $1.9B for Dren Bio’s Bispecific Antibody for Autoimmune Disease
The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can achieve deep B cell depletion, giving it the potential to reset the immune system.
March 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS